Immuno-Sino

Immuno-Sino is a clinical-stage biotechnology company headquartered in Suzhou, China, dedicated to developing innovative T-cell receptor (TCR-T) therapies for solid tumors. The company utilizes a proprietary platform for the identification and optimization of high-affinity TCRs that target intracellular tumor antigens presented by HLA molecules. Its lead candidate, IST-001, is a TCR-T therapy targeting NY-ESO-1, currently undergoing clinical evaluation for indications such as synovial sarcoma and liposarcoma. Immuno-Sino aims to address the limitations of current immunotherapies in solid tumors by enhancing T-cell infiltration and persistence within the tumor microenvironment. The company's pipeline also includes programs targeting MAGE-A3 and other cancer-testis antigens.